Article: Convalescent Plasma for the Treatment of Severe COVID-19.
2021 Volume 15, Page(s) 31–38
Abstract: The COVID-19 pandemic in 2020 is one of the worst catastrophic events in human history. Several non-specific antiviral drugs have been tried to defeat the SARS-CoV-2, with mixed results. Convalescent plasma from patients who have recovered from COVID-19 ... ...
| Abstract | The COVID-19 pandemic in 2020 is one of the worst catastrophic events in human history. Several non-specific antiviral drugs have been tried to defeat the SARS-CoV-2, with mixed results. Convalescent plasma from patients who have recovered from COVID-19 is one of the specific biologic therapies being considered to treat SARS-CoV-2 infection. Preliminary studies have shown that convalescent plasma, containing antibodies able to neutralize SARS-CoV-2, is promising in blocking viral replication and improving patients' clinical symptoms. The results of several ongoing randomized controlled trials are, however, keenly awaited to definitively elucidate the safety and efficacy of this blood component in COVID-19. In this narrative review, we summarize the current evidence from the literature on the treatment of severe COVID-19 with convalescent plasma. A concise overview of the hypothesized mechanisms of action is also presented. |
|---|---|
| Language | English |
| Publishing date | 2021-02-04 |
| Publishing country | New Zealand |
| Document type | Journal Article ; Review |
| ZDB-ID | 2415708-9 |
| ISSN | 1177-5491 ; 1177-5475 |
| ISSN (online) | 1177-5491 |
| ISSN | 1177-5475 |
| DOI | 10.2147/BTT.S272063 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.